Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,162 across all filing types
Latest filing 2015-05-12 Director's Dealing
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2015-05-12 English
10-Q
Interim / Quarterly Report Q1 2015
2015-05-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2015, reporting the financial results for the quarter ended March 31, 2015. It includes a press release as Exhibit 99.1 announcing the quarterly financial results. The text explicitly states it is a current report on Form 8-K and the content is a financial results announcement for a quarter, which corresponds to an Earnings Release (ER). The document length is 3176 characters, which is short and typical for an 8-K earnings release announcement. Therefore, the filing type is Earnings Release (ER).
2015-05-04 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive additional proxy statement material related to a shareholder meeting. It includes information about the annual meeting date, voting instructions, director nominees, and ratification of the independent auditor. It is not the proxy statement itself but additional materials related to it. The document does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive proxy-related content. Therefore, the document fits the Remuneration Information (DEF 14A) category, which covers proxy statements and related materials detailing executive and director compensation and voting matters.
2015-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2015-04-28 English
FORM 4 -
Director's Dealing
2015-04-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.